Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/158599
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

Case Report: Propranolol increases the therapeutic response to temozolomide in a patient with metastatic paraganglioma [version 1; referees: awaiting peer review]

AuthorsDíaz-Castellanos, Miguel-Ángel; Villar Gómez de las Heras, Karina; Díaz-Redondo, Tamara; González-Flores, Encarnación; Albiñana, Virginia CSIC; Botella, Luisa María CSIC ORCID
Issue Date4-Dec-2017
PublisherFaculty of 1000
CitationF1000Research 6:2087 (2017)
AbstractThis case report presents the clinical evolution and management of a patient with a hereditary paraganglioma syndrome. This disease is characterized by rare tumors of neural crest origin that are symmetrically distributed along the paravertebral axis from the base of the skull and neck to the pelvis. In addition, these patients may develop renal cancer, gastrointestinal stromal tumors, pituitary adenomas, and bone metastasis in some cases. To date no successful therapeutic treatment has been reported. Total resection with postoperative radiotherapy and chemotherapy have been advocated, especially for the multiple metastasis. Here we show how the combination of high doses of the beta blocker propranolol (3 mg/Kg/day) and the DNA intercalating agent, temozolomide, has been successful in the treatment of a SDHA metastatic paraganglioma.
Description6 p.-1fig.
Publisher version (URL)http://dx.doi.org/10.12688/f1000research.13185.1
URIhttp://hdl.handle.net/10261/158599
DOI10.12688/f1000research.13185.1
ISSN2046-1402
E-ISSN2046-1402
Appears in Collections:(CIB) Artículos

Files in This Item:
File Description SizeFormat
F1000 Research_2017_Luisa-Maria_Botella.pdfArtículo principal843,14 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work

Google ScholarTM

Check

Altmetric

Dimensions


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.